PTC Therapeutics
PTCT · Nasdaq · United States
Share price · PTCT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PTCT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+11.9%
- 30 Oct 2026-7.0%
- 28 Sep 2026+5.2%
- 31 Jul 2026-9.9%
- 8 May 2026+14.3%
- 29 Apr 2026-8.1%
- 9 Mar 2026+8.9%
Nothing announced by PTCT that day or the session before.
- 16 Jan 2026-4.2%
Nothing announced by PTCT that day or the session before.
- 1 Dec 2025-7.9%
Share of unusual movement by asset
For each asset, the share of PTCT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | AADC (aromatic L-amino acid decarboxylase)Gene therapy / editing | AADC Deficiency | |
| Approved | Phenylalanine hydroxylase (PAH)Small molecule | Phenylketonuria | |
| Phase 3 | 15-lipoxygenase (15-LO)Small molecule | Friedreich Ataxia | |
| Phase 3 | APOC3 mRNARNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere Hypertriglyceridemia | |
| Phase 1/2 | Alpha-galactosidase A (GLA / α-Gal A)Gene therapy / editing | Fabry Disease |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $358M | $105M | $525M+ $1.6B short-term inv. | $52M-$25M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $361M | $99M | $1.1B+ $1.2B short-term inv. | —$129M operating cash flow | report ↗ |
| 2026-Q1 | $273M | $101M | $850M+ $1.1B short-term inv. | $2.8M-$59M operating cash flow | report ↗ |
| 2025-Q3 | $211M | $100M | $686M+ $1.0B short-term inv. | —-$66M operating cash flow | report ↗ |
| 2025-Q2 | $179M | $113M | $1.0B+ $972M short-term inv. | $65M-$58M operating cash flow | report ↗ |
| 2025-Q1 | $1.2B | $109M | $1.5B+ $547M short-term inv. | —$870M operating cash flow | report ↗ |
| 2024-Q3 | $197M | $161M | $540M+ $487M short-term inv. | $107M-$77M operating cash flow | report ↗ |
| 2024-Q2 | $187M | $132M | $669M+ $439M short-term inv. | $99M-$71M operating cash flow | report ↗ |
| 2024-Q1 | $210M | $116M | $565M+ $336M short-term inv. | $92M$71M operating cash flow | report ↗ |
| 2023-Q3 | $197M | $164M | $181M+ $130M short-term inv. | $133M-$15M operating cash flow | report ↗ |
| 2023-Q2 | $214M | $186M | $225M+ $130M short-term inv. | $199M-$14M operating cash flow | report ↗ |
| 2023-Q1 | $220M | $195M | $234M+ $119M short-term inv. | $139M-$29M operating cash flow | report ↗ |
| 2022-Q3 | $217M | $165M | $121M+ $184M short-term inv. | $109M-$38M operating cash flow | report ↗ |
| 2022-Q2 | $166M | $157M | $174M+ $347M short-term inv. | $152M-$55M operating cash flow | report ↗ |
| 2022-Q1 | $149M | $140M | $152M+ $444M short-term inv. | $127M-$97M operating cash flow | report ↗ |
| 2021-Q3 | $139M | $131M | $197M+ $678M short-term inv. | $134M-$51M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.7B | $455M | $998M+ $961M short-term inv. | —$711M operating cash flow | report ↗ |
PTC Therapeutics reported full-year 2025 revenue of $1,730.66M, up 114.5% YoY, with collaboration and license revenue of $998.4M from the votoplam agreement with Novartis contributing substantially. R&D spend was $455.25M, down 14.8% YoY, and the company ended the year with cash and equivalents of $998.33M. Net income was $682.64M for 2025, a swing from the prior-year net loss.
For 2026, PTC guides total product revenue of $700–800 million, a 19–36% increase from 2025, with the majority from Sephience, plus GAAP R&D and SG&A expense of $775–815 million (non-GAAP $680–720 million). Sephience generated $111M in 2025 since its launch, received approvals in Japan and Brazil, and is expected to expand to 20–30 countries by end of 2026. The company also reported FDA alignment on a planned Phase 3 trial (INVEST-HD) for votoplam in Huntington’s disease, with initiation expected in 1H 2026, and noted the FDA indicated an additional study, potentially open-label with a natural history control, is needed for vatiquinone in Friedreich’s ataxia. In December 2025, PTC sold the remainder of its Evrysdi royalty to Royalty Pharma for $240M upfront and up to $60M in milestones.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $807M | $534M | $795M+ $360M short-term inv. | $91M-$108M operating cash flow | report ↗ |
| 2023-FY | $938M | $667M | $610M+ $283M short-term inv. | $157M-$158M operating cash flow | report ↗ |
| 2022-FY | $699M | $652M | $296M+ $131M short-term inv. | $140M-$357M operating cash flow | report ↗ |
| 2021-FY | $539M | $541M | $197M+ $584M short-term inv. | $131M-$251M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 203 sales ($56.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Boulding Mark Elliott · EXEC. VP AND CLO | Option exercise | 2,812 | $25.69 | $72K | Form 4 |
| 2026-11-16 | Boulding Mark Elliott · EXEC. VP AND CLO | Open-market sale | 1,315 | $61.39 | $81K | Form 4 |
| 2026-11-16 | Boulding Mark Elliott · EXEC. VP AND CLO | Open-market sale | 1,288 | $62.22 | $80K | Form 4 |
| 2026-11-16 | Boulding Mark Elliott · EXEC. VP AND CLO | Open-market sale | 209 | $62.90 | $13K | Form 4 |
| 2026-11-16 | Boulding Mark Elliott · EXEC. VP AND CLO | Option exercise (derivative) | 2,812 | — | — | Form 4 |
| 2026-10-14 | SCHMERTZLER MICHAEL · director | Open-market sale | 2,118 | $59.52 | $126K | Form 4 |
| 2026-10-14 | SCHMERTZLER MICHAEL · director | Open-market sale | 382 | $60.14 | $23K | Form 4 |
| 2026-10-09 | Boulding Mark Elliott · EXEC. VP AND CLO | Option exercise | 192 | $39.42 | $8K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 348 reporting institutions held 95.5M shares ($6.4B, 114.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 12,948,717 | $882.2M |
| 2 | RTW INVESTMENTS, LP | 7,746,415 | $527.8M |
| 3 | JANUS HENDERSON GROUP PLC | 7,193,433 | $490.0M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,804,594 | $327.3M |
| 5 | STATE STREET CORP | 4,346,519 | $296.1M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 3,942,610 | $268.6M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3,676,256 | $250.5M |
| 8 | TORONTO DOMINION BANK | 3,025,963 | $206.2M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2,209,954 | $150.6M |
| 10 | ARMISTICE CAPITAL, LLC | 2,074,449 | $141.3M |
| 11 | BANK OF AMERICA CORP /DE/ | 1,886,841 | $128.6M |
| 12 | Hood River Capital Management LLC | 1,664,559 | $113.4M |
| 13 | D. E. Shaw & Co., Inc. | 1,640,381 | $111.8M |
| 14 | FMR LLC | 1,528,362 | $104.1M |
| 15 | TANG CAPITAL MANAGEMENT LLC | 1,500,000 | $102.2M |